MSCopilot app tracks MS symptoms as well as standard tests; studyMSCopilot, a smartphone-based app that is used by patients with multiple sclerosis to gauge how their symptoms are Share XMSCopilot app tracks MS symptoms as well as standard tests; studyhttps://pharmaphorum.com/news/mscopilot-app-tracks-ms-symptoms-as-well-as-standard-tests-study/
Consternation as NICE rejects Janssen MS drug PonvoryNICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s Share XConsternation as NICE rejects Janssen MS drug Ponvoryhttps://pharmaphorum.com/news/consternation-as-nice-rejects-janssen-ms-drug-ponvory/
Biogen builds MS pipeline via $125m deal with China’s InnoCareBiogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese Share XBiogen builds MS pipeline via $125m deal with China’s InnoCarehttps://pharmaphorum.com/news/biogen-builds-ms-pipeline-via-125m-deal-with-chinas-innocare/
After FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MSSanofi’s Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple Share XAfter FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MShttps://pharmaphorum.com/news/after-fda-rejection-eu-says-yes-to-sanofis-aubagio-in-children/
Foods, supplements, and medicine: the new frontier in chronic disease treatmentChronic diseases are the biggest threat to our global socio-economic development. Lifestyle diseases including heart disease, neuro-degenerative disease, Share XFoods, supplements, and medicine: the new frontier in chronic disease treatmenthttps://pharmaphorum.com/partner-content/foods-supplements-and-medicine-the-new-frontier-in-chronic-disease-treatment/
NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosisNICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that Share XNICE says final ‘no’ to BMS’ Zeposia for multiple sclerosishttps://pharmaphorum.com/news/nice-says-final-no-to-bms-zeposia-for-multiple-sclerosis/
NICE says yes to Novartis’ multiple sclerosis therapy KesimptaNovartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just Share XNICE says yes to Novartis’ multiple sclerosis therapy Kesimptahttps://pharmaphorum.com/news/nice-says-yes-to-novartis-multiple-sclerosis-therapy-kesimpta/
Teva faces EU antitrust probe over MS drug CopaxoneThe European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company Share XTeva faces EU antitrust probe over MS drug Copaxonehttps://pharmaphorum.com/news/teva-faces-eu-antitrust-probe-over-ms-drug-copaxone/
COVID-19 increased demands on carers’ wellbeing, study findsCOVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, Share XCOVID-19 increased demands on carers’ wellbeing, study findshttps://pharmaphorum.com/news/covid-19-increased-demands-on-informal-carers-wellbeing-study-finds/
